Hepatic and Biliary Tract > uHCC
Select trial for more information
Area under investigation,BTCs,HCC,uHCC=true
Tumor
BTCs after resection with curative intent
Trial Identifier
NCT06109779
Phase
III
Stage
Early
Regimen
Rilvegostomig + investigator's choice of chemotherapy; placebo + investigator's choice of chemotherapy
Advanced BTC including intra-hepatic or extra-hepatic CCA and GBC
NCT07221253
Rilvegostomig + gemcitabine/cisplatin; durvalumab + gemcitabine/cisplatin
Locally advanced or metastatic and/or unresectable HCC
NCT06921785
Tremelimumab IV + rilvegostomig IV + bevacizumab IV; rilvegostomig IV + bevacizumab IV; atezolizumab IV + bevacizumab IV
GPC3+ Advanced/Recurrent HCC
NCT06084884
II-III
BCLC Stage B (not amenable to locoregional therapy) or BCLC Stage C prior to apheresis
AZD7003
Advanced solid tumors (breast cancer, BTCs, ovarian cancer, endometrial cancer, squamous NSCLC)
NCT05123482
I/IIa
Puxitatug samrotecan monotherapy; puxitatug samrotecan + rilvegostomig; puxitatug samrotecan + rilvegostomig + palacaparib
Claudin 18.2-positive advanced solid tumors (gastric/GEJ cancer, pancreatic adenocarcinoma, BTCs)
NCT06219941
II
Sonesitatug vedotin; sonesitatug vedotin + chemotherapy
Advanced HER2-expressing BTCs, 1L
NCT06467357
T-DXd + rilvegostomig; T-DXd; gemcitabine + cisplatin + durvalumab
fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.
Advanced hepatobiliary cancers (HCC, BTCs)
NCT05775159
Unresectable, advanced or metastatic
In HCC - volrustomig monotherapy; volrustomig + bevacizumab or lenvatinib or rilvegostomig + bevacizumab; rilvegostomig + bevacizumab. In BTCs - volrustomig + gemcitabine and cisplatin; rilvegostomig + gemcitabine and cisplatin
Advanced solid tumors (advanced/metastatic ovarian cancer, HR+/HER2- breast cancer, TNBC, pancreatic cancer, prostate cancer, NSCLC, SCLC, gastric cancer, biliary cancer, cervical cancer, endometrial cancer, CRC, bladder cancer)
NCT04644068
Saruparib; saruparib + paclitaxel; saruparib + carboplatin ± paclitaxel; saruparib + T-DXd; saruparib + Dato-DXd; saruparib + camizestrant
GPC3-positive advanced/recurrent HCC
NCT06590246
I/II
Part A1 (dose escalation): AZD7003; Part A2 (dose expansion): AZD7003
Advanced solid tumors (endometrial, gastric, mCRPC, ovarian, colorectal, metastatic urothelial carcinoma, BTCs)
NCT05489211
Dato-DXd; Dato-DXd + capecitabine or 5-FU; Dato-DXd + prednisone or prednisolone; Dato-DXd + carboplatin + bevacizumab followed by Dato-DXd + bevacizumab; Dato-DXd + bevacizumab + (5-FU + leucovorin or capecitabine); Dato-DXd+ 5-FU/leucovorin or capecitabine + bevacizumab; Dato-DXd + rilvegostomig or carboplatin/cisplatin
